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http://dx.doi.org/10.1016/j.chembiol.2014.04.004In this issue of Chemistry & Biology, Cokol and colleagues report a systematic study of drug interactions be-
tween antifungal compounds. Suppressive drug interactions occur more frequently than previously realized
and come in different flavors with interesting implications.When two drugs are combined, they
may interact synergistically or antago-
nistically; for synergistic interactions,
the combined drug effect on growth is
stronger than expected, while for antag-
onistic interactions it is weaker (Figures
1A–1C) (Greco et al., 1995; Loewe,
1928). Suppressive interactions are hy-
per-antagonistic cases in which the
addition of one drug on top of another
actually increases growth—a surprising
effect, given that both drugs alone
inhibit growth (Figure 1D). Drug interac-
tions are analogous to genetic epistasis
in which the combined effect of genetic
perturbations is characterized by its de-
viation from additivity (Poelwijk et al.,
2007). Most research has focused on
synergistic drugs, because they allow
the use of lower drug dosages, which
can facilitate treatments. In contrast,
antagonistic and suppressive drug inter-
actions have received less attention,
although they have been known for a
long time. Over 140 years ago, Fraser
measured a two-drug response surface
in rabbits and observed that the effect
of Physostigma venenosum extract
was suppressed by atropine (Fraser,
1871)—rabbits given just the right dose
of both drugs were hopping around
happily, whereas the same dose of
physostigma alone killed the animals
within minutes.
A possible reason for the lack of atten-
tion to suppressive drug combinations is
that they can evidently impair treatment
efficiency. Interestingly though, recent
work on antibiotic combinations has
shown that suppressive drug combina-
tions can lead to selection against drug
resistance (Chait et al., 2007). Thus, sup-
pressive drug interactions may have
important implications for the long-
term success of treatments. Beyondmedical applications, drug combinations
are generally an important means of
controlled cellular perturbation. Com-
pared to genetic perturbations, drugs
have the advantage that their dose can
be altered continuously, which may facili-
tate the elucidation of complex rela-
tionships between cellular functions.
However, few systematic studies charac-
terizing pairwise interactions between
large sets of drugs exist, and in particular
the prevalence of suppressive interac-
tions in these networks has not been sys-
tematically mapped.
In this issue of Chemistry & Biology,
Cokol et al. (2014) investigated the perva-
siveness of suppression between many
antifungal drug pairs in Saccharomyces
cerevisiae. They found that 17% of 175
tested drug pairs showed suppressive
interactions. This high frequency of sup-
pressive interactions is a conservative es-
timate of the prevalence of suppression
between antifungals, because the drug
pairs in this data set were originally cho-
sen in an attempt to identify synergistic
interactions (Cokol et al., 2011). By assay-
ing another 40 drug combinations (con-
sisting of 10 unbiased drugs tested
against 4 drugs with a tendency to sup-
press or be suppressed), the authors
found an even higher fraction of suppres-
sive drug interactions of 38%. Overall,
these observations suggest that suppres-
sion between antifungals occurs quite
frequently.
Suppressive interactions typically have
a direction, i.e., one drug suppresses the
effect of the other, but not the other way
around (Figure 1D). Interestingly, apart
from such directed suppression, Cokol
et al. (2014) observed several recipro-
cally suppressive interactions in which
drug A suppressed drug B and vice
versa (Figures 1E and 1F). This specialChemistry & Biology 21, April 24, 2014type of suppression is interesting,
because theoretical arguments suggest
that a reciprocally suppressive drug
combination as in Figure 1E can lead to
selection against mutants that are resis-
tant to either drug alone (Chait et al.,
2007), leaving only mutations that confer
resistance to both drugs simultaneously
as a viable path for the emergence of
drug resistance. Such mutations are ex-
pected to be rare, and reciprocally sup-
pressive drugs could thus slow down
the evolution of drug resistance: at least
as long as the drug interaction itself is
not altered by mutations. Although
most examples of reciprocal suppres-
sion reported by Cokol et al. (2014) are
more similar to the case in Figure 1F, it
will be interesting to test these newly
found reciprocally suppressive drug
pairs for their ability to select against
drug resistance.
Another observation made by the
authors is that the antifungal compound
Bromopyruvate (Bro) often suppressed
other drugs while another (Staurosporine
[Sta]) was more often suppressed (Cokol
et al., 2014). This extends previous find-
ings that certain antifungals often show
synergistic interactions with other drugs
in yeast (Cokol et al., 2011) and that
aminoglycoside antibiotics often interact
synergistically with other antibiotics in
bacteria (Yeh et al., 2006). Overall, a
general property of drug interaction
networks is emerging; certain drugs form
network hubs that are highly enriched for
the same type of interaction with other
drugs.
Intriguingly, this observation suggests
that there may be general underlying
causes of these drug interactions; e.g., a
drug could trigger the upregulation of a
multidrug efflux pump protecting cells
from many other drugs, which would beª2014 Elsevier Ltd All rights reserved 439
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Figure 1. Drug Interactions
Shown are schematic response surfaces representing growth of a microbial culture in 535 concentration
matrices. The growth response to the drugs is depicted as the area under the growth curve. The dose of
both drugs that is needed to reach the black diamond on the minimal inhibitory concentration (MIC) line
(gray) is indicated by pills of corresponding size.
(A) Additivity: adding a half-MIC dose of each drug A and drug B leads to the same growth inhibition as a
full-MIC dose of either drug A or drug B.
(B) Synergy: the drugs together inhibit growth more strongly than expected from additivity.
(C) Antagonism: the combined effect of the drugs is weaker than expected from additivity.
(D) Directional suppression: a higher dose of drug B is needed to reach the MIC line in presence of drug A
than in its absence.
(E and F) Reciprocal suppression: both drugs suppress each other.
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these drugs. This is currently speculation
though, and, generally, little is known440 Chemistry & Biology 21, April 24, 2014 ªabout the causes of drug interactions.
To gain insight into the causes of a
selected suppressive interaction (be-2014 Elsevier Ltd All rights reservedtween Bro and Sta) Cokol et al. (2014)
used haploinsufficiency profiling and
homozygous deletion profiling. Although
these chemogenomic analyses yielded
valuable insights into the individual drug
effects (e.g., the effect of Bro was modu-
lated in acs2D/ACS2 and erg10D/ERG10
mutants, which both affect the same
metabolic pathway), they could not reveal
the mechanism of suppression between
the two drugs. Their work further adds a
note of caution to drug interaction
studies; a small pH change in the growth
medium, due to the addition of certain
drugs, was found to suppress certain
other drugs.
The difficulty in identifying the causes of
drug interactions may be due to complex
effects on multiple cellular functions. An
example from bacteria where the
interaction mechanism has been charac-
terized is the suppression between trans-
lation andDNA synthesis inhibitors. These
were shown to be caused by a nonoptimal
regulation of ribosome production under
DNA synthesis inhibitors, which is partly
corrected by the translation inhibitor
(Bollenbach et al., 2009). It will be an
interesting direction for future research
to elucidate the causes of the newly
observed suppressive interactions be-
tween antifungals (Cokol et al., 2014).REFERENCES
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